Loading clinical trials...
Loading clinical trials...
An Open-Label Study Evaluating the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
Conditions
Interventions
CSB-001 Ophthalmic Solution 0.1%
Locations
6
United States
Loma Linda University Eye Institute
Loma Linda, California, United States
Midwest Cornea Associates, LLC
Carmel, Indiana, United States
Francis Price Jr, MD
Indianapolis, Indiana, United States
Minnesota Eye Consultants
Minnetonka, Minnesota, United States
Legacy Devers Eye Institute
Portland, Oregon, United States
Stuart A. Terry, MD PA
San Antonio, Texas, United States
Start Date
May 15, 2024
Primary Completion Date
November 1, 2025
Completion Date
May 1, 2026
Last Updated
June 5, 2025
NCT07119580
NCT02318485
NCT03288844
NCT03217435
NCT02568527
NCT03015779
Lead Sponsor
Claris Biotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions